To discuss the complexities of diagnosing and treating colorectal cancer (CRC) in pregnant patients, emphasizing the importance of a multidisciplinary approach to ensure both maternal and fetal health.
Key Findings:
Colorectal cancer is increasingly diagnosed in pregnant women, with a significant proportion presenting with metastatic disease.
Imaging modalities must be carefully selected to minimize fetal exposure to radiation.
Chemotherapy is generally avoided in the first trimester due to risks of teratogenicity, while second and third trimesters show limited risks, impacting treatment decisions.
Interpretation:
The management of colorectal cancer during pregnancy is complex and necessitates careful consideration of both maternal and fetal health, highlighting the need for individualized treatment plans tailored to each patient's circumstances.
Limitations:
Limited data on the teratogenic effects of chemotherapy due to exclusion of pregnant patients from clinical trials, which may impact clinical decision-making.
Variability in drug effects based on gestational age and individual patient factors.
Conclusion:
A multidisciplinary approach is essential for the effective management of colorectal cancer in pregnant patients, balancing treatment efficacy with safety for both mother and fetus, and underscoring the need for ongoing research in this area.
